journal
https://read.qxmd.com/read/38619722/reduction-in-diabetes-related-hospitalizations-and-medical-costs-after-dexcom-g6-continuous-glucose-monitor-initiation-in-people-with-type-2-diabetes-using-intensive-insulin-therapy
#1
JOURNAL ARTICLE
Katia L Hannah, Poorva M Nemlekar, Courtney R Green, Gregory J Norman
INTRODUCTION: Some people with type 2 diabetes (T2D) require intensive insulin therapy to manage their diabetes. This can increase the risk of diabetes-related hospitalizations. We hypothesize that initiation of real-time continuous glucose monitoring (RT-CGM), which continuously measures a user's glucose values and provides threshold- and trend-based alerts, will reduce diabetes-related emergency department (ED) and inpatient hospitalizations and concomitant costs. METHODS: A retrospective analysis of US healthcare claims data using Optum's de-identified Clinformatics® Data Mart database was performed...
April 15, 2024: Advances in Therapy
https://read.qxmd.com/read/38619721/real-world-treatment-patterns-and-healthcare-resource-use-for-ulcerative-colitis-and-crohn-s-disease-in-italy
#2
JOURNAL ARTICLE
Melania Dovizio, Susanne Hartz, Carlotta Buzzoni, Isabel Redondo, Marijana Nedeljkovic Protic, Domenico Birra, Valentina Perrone, Chiara Veronesi, Luca Degli Esposti, Alessandro Armuzzi
INTRODUCTION: Real-world data are used to inform decision-makers and optimise therapeutic management for patients with ulcerative colitis (UC) and Crohn's disease (CD). We analysed data on the epidemiology (by using proxies of prevalence and incidence), patient characteristics, treatment patterns and associated healthcare direct costs for the management of patients with UC and patients with CD in Italy. METHODS: This retrospective observational study used administrative databases from eight Local Health Units geographically distributed across Italy...
April 15, 2024: Advances in Therapy
https://read.qxmd.com/read/38619720/treatment-free-interval-a-novel-approach-to-assessing-real-world-treatment-effectiveness-and-economic-impact-among-patients-with-irritable-bowel-syndrome-with-diarrhea
#3
JOURNAL ARTICLE
Brian E Lacy, Patrick Gagnon-Sanschagrin, Zeev Heimanson, Rebecca Bungay, Remi Bellefleur, Annie Guérin, Brock Bumpass, Danellys Borroto, George Joseph, Ankur A Dashputre
INTRODUCTION: Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline in the USA. METHODS: Adult patients (18-64 years) with IBS-D and ≥ 1 rifaximin or eluxadoline prescription were identified in the IQVIA PharMetrics® Plus database (10/01/2015-12/31/2021) and classified into two mutually exclusive cohorts (i...
April 15, 2024: Advances in Therapy
https://read.qxmd.com/read/38619719/real-world-effectiveness-and-safety-of-ramucirumab-as-a-second-line-treatment-for-patients-with-unresectable-advanced-or-metastatic-gastric-gastroesophageal-junction-adenocarcinoma-in-japan-and-south-korea-a-systematic-literature-review
#4
REVIEW
Xiaotian Zhang, Li Zhou, Chan Zhou, Lin Shen
INTRODUCTION: Gastric cancer has the highest incidence and mortality in Eastern Asia. The efficacy and safety of ramucirumab (RAM) monotherapy or in combination with paclitaxel (PTX) for patients with unresectable advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEA) have been established in clinical trials. To assess the effectiveness and safety of RAM or RAM-based therapy as a second-line treatment in real-world clinical practice in Eastern Asia and to pave the way for future research, a systematic literature review (SLR) was conducted...
April 15, 2024: Advances in Therapy
https://read.qxmd.com/read/38616242/rationale-and-design-of-the-improve-trial-a-multicenter-randomized-controlled-open-label-blinded-endpoint-trial-assessing-the-efficacy-of-remote-ischemic-conditioning-in-patients-undergoing-off-pump-coronary-artery-bypass-grafting
#5
JOURNAL ARTICLE
Yang Yan, Changying Zhao, Jialan Niu, Pengyun Yan, Jing Li, Duolao Wang, Guoliang Li
INTRODUCTION: Despite the appearance of off-pump coronary artery bypass grafting (CABG), ischemia-reperfusion injury (IRI) in the perioperative period still arouses concerns of clinicians. Remote ischemic conditioning (RIC) is the process of repeated ischemia and reperfusion in the peripheral vessels, which is proven to reduce IRI in vital organs. However, the effect of RIC in patients undergoing off-pump CABG is still unclear. METHODS: This IMPROVE trial is a national, multicenter, randomized, controlled, open-label, blinded-endpoint clinical trial designed to assess whether RIC intervention can improve short-term prognosis of patients undergoing off-pump CABG...
April 15, 2024: Advances in Therapy
https://read.qxmd.com/read/38616241/comparative-effectiveness-of-valoctocogene-roxaparvovec-and-prophylactic-factor%C3%A2-viii-replacement-in-severe-hemophilia%C3%A2-a
#6
JOURNAL ARTICLE
Johannes Oldenburg, Herve Chambost, Hai Liu, Charles Hawes, Xiaojun You, Xinqun Yang, Vanessa Newman, Tara M Robinson, Anthony J Hatswell, David Hinds, Sandra Santos, Margareth Ozelo
INTRODUCTION: A prospective, non-interventional study (270-902) followed 294 adults with severe hemophilia A (SHA) receiving prophylactic factor VIII (FVIII). From these participants, 112 rolled over into a single-arm, multicenter, phase 3 trial (GENEr8-1; NCT03370913) that evaluated efficacy and safety of valoctocogene roxaparvovec, a gene therapy that provides endogenous FVIII in individuals with SHA. Participants from 270-902 who did not roll over provide an opportunity for a contemporaneous external control...
April 15, 2024: Advances in Therapy
https://read.qxmd.com/read/38598114/correction-to-real-world-safety-and-effectiveness-of-an-8-week-regimen-of-glecaprevir-pibrentasvir-in-patients-with-hepatitis%C3%A2-c-and-cirrhosis
#7
Mei Lu, Loralee B Rupp, Christina Melkonian, Sheri Trudeau, Yihe G Daida, Mark A Schmidt, Stuart C Gordon
No abstract text is available yet for this article.
April 10, 2024: Advances in Therapy
https://read.qxmd.com/read/38573483/exploring-the-content-validity-of-the-unified-wilson-disease-rating-scale-insights-from-qualitative-research
#8
JOURNAL ARTICLE
Stella Karantzoulis, Karli Heuer, Nicole Sparling, Brian Meltzer, Megan Teynor
INTRODUCTION: Wilson disease (WD) is a rare metabolic disorder of impaired copper transport manifesting in hepatic, neurological, and psychiatric symptoms. To evaluate the clinical symptoms of WD in clinical trials, a group of clinicians created the Unified Wilson Disease Rating Scale (UWDRS). Content validity of this scale has not been established. The aim of this study was to evaluate the content validity of the UWDRS Part II from the patient perspective. METHODS: This study utilized multiple qualitative research methods including concept elicitation interviews, concept/instrument mapping, and cognitive debriefing interviews...
April 4, 2024: Advances in Therapy
https://read.qxmd.com/read/38573482/safety-and-efficacy-of-pegcetacoplan-in-adult-patients-with-paroxysmal-nocturnal-hemoglobinuria-over-48%C3%A2-weeks-307-open-label-extension-study
#9
JOURNAL ARTICLE
Christopher J Patriquin, Andrija Bogdanovic, Morag Griffin, Richard J Kelly, Jaroslaw P Maciejewski, Brian Mulherin, Régis Peffault de Latour, Alexander Röth, Veena Selvaratnam, Jeffrey Szer, Mohammed Al-Adhami, Regina Horneff, Lisa Tan, Michael Yeh, Jens Panse
INTRODUCTION: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening disease characterized by complement-mediated hemolysis and thrombosis. Pegcetacoplan, the first targeted complement component 3 (C3) PNH therapy, was safe and efficacious in treatment-naive and pre-treated patients with PNH in five clinical trials. METHODS: The 307 open-label extension (OLE) study (NCT03531255) is a non-randomized, multicenter extension study of long-term safety and efficacy of pegcetacoplan in adult patients with PNH who completed a pegcetacoplan parent study...
April 4, 2024: Advances in Therapy
https://read.qxmd.com/read/38557807/perceptions-and-experiences-of-people-with-obesity-and-type-2-diabetes-around-appetite-and-eating-behaviors-a-qualitative-study
#10
JOURNAL ARTICLE
Jiat Ling Poon, Louise OHara, Helen Kendal, Kate Sully, Margaret Guy, Helena Bradley, Chloe Tolley, Brad Mason
INTRODUCTION: Chronic weight management and treatments for type 2 diabetes (T2D) involve a combination of lifestyle-based (diet, exercise) and pharmaceutical interventions. In people with obesity or T2D, understanding the impact of drivers/triggers on appetite and eating behaviors can be crucial to successful medical management. This study aimed to characterize perceptions and experiences regarding appetite and eating behaviors among people with obesity or T2D and identify drivers/triggers of food choices...
April 1, 2024: Advances in Therapy
https://read.qxmd.com/read/38554238/modelling-treatment-sequences-in-immunology-optimizing-patient-outcomes
#11
JOURNAL ARTICLE
Rose J Hart, Fareen Hassan, Sarah Alulis, Karl W Patterson, Jennifer Norma Barthelmes, Jennifer H Boer, Dawn Lee
INTRODUCTION: For some immune-mediated disorders, despite the range of therapies available there is limited evidence on which treatment sequences are best for patients and healthcare systems. We investigated how their selection can impact outcomes in an Italian setting. METHODS: A 3-year state-transition treatment-sequencing model calculated potential effectiveness improvements and budget reallocation considerations associated with implementing optimal sequences in ankylosing spondylitis (AS), Crohn's disease (CD), non-radiographic axial spondyloarthritis (NR-AxSpA), plaque psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), and ulcerative colitis (UC)...
March 30, 2024: Advances in Therapy
https://read.qxmd.com/read/38532238/pharmacological-basis-of-differences-in-dose-response-dose-equivalence-and-duration-of-action-of-inhaled-corticosteroids
#12
JOURNAL ARTICLE
Peter T Daley-Yates, Bhumika Aggarwal, Maximilian Plank
INTRODUCTION: Asthma treatment guidelines classify inhaled corticosteroid (ICS) regimens as low, medium, or high dose. However, efficacy and safety are not independently assessed accordingly. Moreover, differences in ICS duration of action are not considered when a dose regimen is selected. We investigated the efficacy and safety implications of these limitations for available ICS molecules. METHODS: Published pharmacodynamic and pharmacokinetic parameters were used, alongside physiological and pharmacological principles, to estimate the efficacy and safety of available ICS molecules...
March 27, 2024: Advances in Therapy
https://read.qxmd.com/read/38520502/real-world-adherence-to-and-persistence-with-vibegron-in-patients-with-overactive-bladder-a-retrospective-claims-analysis
#13
JOURNAL ARTICLE
Benjamin Chastek, Adam Carrera, Christina Landis, Daniel Snyder, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Michael Kennelly, David Staskin
INTRODUCTION: Vibegron is a β3 -adrenergic receptor agonist approved for overactive bladder (OAB). This analysis assessed real-world adherence and persistence with vibegron in patients with OAB, along with demographics and clinical characteristics associated with adherence and persistence. METHODS: This retrospective study used the Optum Research Database to identify patients treated with vibegron from April 2021 to August 2022 (identification period). Patients had ≥ 60 days of continuous pharmacy coverage in a commercial or Medicare Advantage plan following the index fill (follow-up)...
March 23, 2024: Advances in Therapy
https://read.qxmd.com/read/38520501/assessing-the%C3%A2-effects-of-metabolic-disruption-body-mass-index-and-inflammation-on-depressive-symptoms-in-post-covid-19-condition-a-randomized-controlled-trial%C3%A2-on-vortioxetine
#14
JOURNAL ARTICLE
Angela T H Kwan, Ziji Guo, Felicia Ceban, Gia Han Le, Sabrina Wong, Kayla M Teopiz, Taeho Greg Rhee, Roger Ho, Joshua D Di Vincenzo, Sebastian Badulescu, Shakila Meshkat, Bing Cao, Joshua D Rosenblat, Giacomo d'Andrea, Donovan A Dev, Lee Phan, Mehala Subramaniapillai, Roger S McIntyre
INTRODUCTION: To date, there are no therapeutics that have gained regulatory approval by the United States Food and Drug Administration (FDA) for the treatment of post-COVID-19 condition (PCC), a debilitating condition characterized by cognitive impairment and mood symptoms. Additionally, persistent inflammation, metabolic dysfunction, and risks associated with an elevated body mass index (BMI) have been observed. Herein, we aimed to assess the efficacy of vortioxetine in improving depressive symptoms among individuals with PCC,  as modulated by inflammation, metabolic dysfunction, and BMI...
March 23, 2024: Advances in Therapy
https://read.qxmd.com/read/38514505/-totality-of-evidence-approach-in-the-development-of-gp2017-an-approved-adalimumab-biosimilar
#15
REVIEW
Norman Gaylis, Charlotte Both, Lena Lemke, Oliver von Richter, Paul Yamauchi
INTRODUCTION: Hyrimoz® , (GP2017 [SDZ-ADL]), is a biosimilar to Humira® (REF-ADL). SDZ-ADL was approved in 2018 by both the United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) for the indications of REF-ADL not protected by orphan exclusivity. In 2023, the US FDA and EMA also approved a citrate-free high-concentration formulation (HCF) of SDZ-ADL. TOTALITY OF EVIDENCE-THE APPROACH: Approval of SDZ-ADL was based on data gathered using the US FDA, EMA and World Health Organization (WHO)-recommended step-wise Totality of Evidence approach...
March 21, 2024: Advances in Therapy
https://read.qxmd.com/read/38512540/real-world-outcomes-of-individualized-targeted-therapy-with-insulin-glargine-300%C3%A2-units-ml-in-insulin-na%C3%A3-ve-korean-people-with-type%C3%A2-2-diabetes-tobe-study
#16
JOURNAL ARTICLE
Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Jae-Myung Yu, Hye Soon Kim, Hyun Jin Kim, Won Kim, Dong Han Kim, Hak Chul Jang
INTRODUCTION: The TOujeo BEyond glucose control (TOBE) study evaluated clinical outcomes with insulin glargine 300 units/mL (Gla-300) in insulin-naïve Korean people with type 2 diabetes mellitus (T2DM) in a real-world setting. METHODS: This 24-week, prospective, non-interventional, multicenter, open-label, single-arm, observational study included adults aged ≥ 20 years with T2DM suboptimally controlled with oral hypoglycemic agents and/or glucagon-like peptide 1 receptor agonists who require basal insulin...
March 21, 2024: Advances in Therapy
https://read.qxmd.com/read/38509433/clinical-management-of-patients-with-non-small-cell-lung-cancer-brain-metastases-and-actionable-genomic-alterations-a-systematic-literature-review
#17
REVIEW
Mustafa Khasraw, Priyanka Yalamanchili, Anu Santhanagopal, Chuntao Wu, Maribel Salas, Jie Meng, Maha Karnoub, Stephen Esker, Enriqueta Felip
INTRODUCTION: Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis. During the disease course, 25-50% of patients will develop BrMs. Despite available treatments, survival rates for patients with NSCLC and BrMs remain low, and their overall prognosis is poor. Even with newer agents for NSCLC, options for treating BrMs can be limited by their ineffective transport across the blood-brain barrier (BBB) and the unique brain tumor microenvironment...
March 21, 2024: Advances in Therapy
https://read.qxmd.com/read/38494543/matching-adjusted-indirect-comparison-of-brexucabtagene-autoleucel-zuma-2-and-pirtobrutinib-bruin-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-previously-treated-with-a-covalent-bruton-tyrosine-kinase%C3%A2-inhibitor
#18
JOURNAL ARTICLE
Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sally W Wade, Ana Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia T Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal Shah
INTRODUCTION: Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) often require multiple lines of treatment and have a poor prognosis, particularly after failing covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy. Newer treatments such as brexucabtagene autoleucel (brexu-cel, chimeric antigen receptor T cell therapy) and pirtobrutinib (non-covalent BTKi) show promise in improving outcomes. METHODS: Without direct comparative evidence, an unanchored matching-adjusted indirect comparison was conducted to estimate the relative treatment effects of brexu-cel and pirtobrutinib for post-cBTKi R/R MCL...
March 18, 2024: Advances in Therapy
https://read.qxmd.com/read/38494542/adjusted-indirect-treatment-comparison-of-progression-free-survival-with-d-rd-and-vrd-based-on-maia-and-swog-s0777-individual-patient-level-data
#19
JOURNAL ARTICLE
Brian G M Durie, Shaji K Kumar, Eric M Ammann, Alex Z Fu, Shuchita Kaila, Annette Lam, Saad Z Usmani, Thierry Facon
INTRODUCTION: Daratumumab plus lenalidomide and dexamethasone (D-Rd) and bortezomib plus lenalidomide and dexamethasone (VRd) are commonly used treatment combinations for transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). D-Rd and VRd demonstrated superior efficacy relative to lenalidomide and dexamethasone (Rd) in the MAIA and SWOG S0777 trials, respectively, but have not been compared directly in a head-to-head trial. Naïve comparisons of efficacy across the two trials may be biased because MAIA enrolled only TIE patients (median age 73 years), whereas SWOG S0777 enrolled both TIE patients and transplant-eligible patients who chose to defer/refuse frontline stem cell transplantation (median age 63 years)...
March 18, 2024: Advances in Therapy
https://read.qxmd.com/read/38494541/enhancing-drug-management-cost-savings-and-staff-satisfaction-in-anesthesiology-a-quality-improvement-project-in-a-chinese-tertiary-hospital
#20
JOURNAL ARTICLE
Xiaomin Xing, Haijun Qu, Longyuan Wang, Xiaojia Hao, Yalan Zhong, Fanbo Jing
INTRODUCTION: In alignment with China's national directive for improved drug management in anesthesiology, the Affiliated Hospital of Qingdao University initiated a quality improvement project, aiming to tackle the prevailing challenges of inefficiencies in drug administration, escalating drug costs, and the notable communication gap between pharmacists and anesthesiologists. METHODS: We employed a Plan-Do-Study-Act methodology to establish a pharmacy team and execute a multidimensional pharmaceutical intervention...
March 18, 2024: Advances in Therapy
journal
journal
29381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.